Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
about
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine modelsSystematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanomaDendritic cell-based vaccine efficacy: aiming for hot spotsWhich comes first: the antigen or the adjuvant?Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancerDepletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide.Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvantIt's time to bring dendritic cell therapy to type 1 diabetes.IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory EffectsOil-based emulsion vaccine adjuvants.Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.Modes of action of TLR7 agonists in cancer therapy.Myeloid-derived suppressor cells as effectors of immune suppression in cancer.Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells.Is Infant Immunity Actively Suppressed or Immature?TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells.Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model.Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine.Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
P2860
Q27012618-026C857D-58DF-453F-8288-84C656B748F0Q28067023-72AF0064-A114-40D1-A492-FF87276CD5E9Q28082680-B70B53EB-EF31-4C7F-ABBC-038B71056E84Q33872575-27EB2FEE-FACE-49FB-8A9D-49E8C13BD833Q35623804-C3645A2C-A005-4D59-B57C-775223ECE74DQ35886752-81507871-3153-4EA4-A48C-C7A9C7447CF5Q36545286-5E47360E-1013-4B88-9A28-5F063BDA5673Q37198471-63B992C1-104C-4BBA-AC89-13725291B30AQ37670174-51E06667-7D87-4B7B-A808-667EDC63AE4CQ37709350-97F577CF-08AD-44BE-97DC-069BE3157638Q38103581-EFE3C45C-B7D6-4CB2-9458-46DE18942095Q38195599-6A7E2D42-4EE9-4B6E-9882-6F200BB615AAQ38235845-125D4DC5-0229-4A10-9B16-AA1D83270F93Q38261273-D11E73B0-D9E8-4C51-B8BD-896161E2EC2BQ38271879-AF5D192C-9988-4A4E-9E7E-DA27B6E660B3Q38864758-4409E339-8A86-4685-A7D9-94232F5F75B4Q39079690-EE4E7187-1D35-4528-8C1A-81AA65067DBCQ41646010-08F50772-4BE7-4470-BA49-D41FF2DDC069Q49977478-DE5A675D-EDE9-459E-83AB-AF542BA78B6CQ50220559-68C63B20-F47B-4B81-8D00-A3B772654E09Q52649737-776D917C-A2AE-4E5D-BCDE-5BDC8ACB9AB1Q55397871-A3337B95-0F1D-402F-9D9E-A387D5C40680Q58692202-EB08F218-7662-46CC-A803-52CEC7E4EE86
P2860
Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Dendritic cell-activating vacc ...... on of immunosuppressive cells.
@ast
Dendritic cell-activating vacc ...... on of immunosuppressive cells.
@en
type
label
Dendritic cell-activating vacc ...... on of immunosuppressive cells.
@ast
Dendritic cell-activating vacc ...... on of immunosuppressive cells.
@en
prefLabel
Dendritic cell-activating vacc ...... on of immunosuppressive cells.
@ast
Dendritic cell-activating vacc ...... on of immunosuppressive cells.
@en
P2093
P2860
P1476
Dendritic cell-activating vacc ...... on of immunosuppressive cells.
@en
P2093
Carmen M Berger
Gregory E Holt
Lauren Rastetter
Mary L Disis
Wolfgang M Wagner
Yushe Dang
P2860
P304
P356
10.1158/1078-0432.CCR-12-0113
P407
P577
2012-04-17T00:00:00Z